Business Wire

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
FiercePharma

FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Wom

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
Targeted Oncology

Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.
EurekAlert!

Pyrotinib and fulvestrant combination shows promising efficacy for HR+/HER2+ metastatic breast cancer patients

A total of 62 patients were initially screened across five study centers for eligibility in this study. Of these, 15 patients were excluded due to various reasons: 10 failed the screening, 3 declined ...